Immunotherapy Drug Articles & Analysis: Older
10 articles found
The classification of anti-tumor APIs often falls into four main types: chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormone therapy drugs. ...
These services include developing targeted therapies, immunotherapy, and inhibitors and drugs. Each stage must undergo rigorous quality testing to achieve the highest safety standards. ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. Alfa Cytology, celebrated for its cutting-edge biotech solutions and extensive tumor research expertise, has recently introduced brain tumor drug development services, designed to empower researchers in understanding the intricacies and unique challenges associated with brain ...
The immunosuppressive microenvironment shaped by B7-H3 helps cancer cells avoid immune destruction. [2] Strategies for Targeting B7-H3 in Immunotherapy The advantages of developing targeted drugs against B7-H3 in immunotherapy are as follows: (1) B7-H3 is expressed in most tumors, and inhibiting this target can significantly impact tumor growth ...
The company has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for immune and cancer research. As immunotherapy gains widespread use, increasing attention is being focused on T-cell clone diversity and clonality, which is crucial for evaluating the effectiveness ...
Results have been shown to be safe from several clinical trials of immunotherapy drugs targeting mesothelin, including immunotoxin therapy, monoclonal antibodies, vaccines, antibody-conjugated drugs, CAR T cells, CAR-NK cells, and α-targeted therapies. ...
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. ...
Their goal is to identify markers found on the surface of patients' immune cells that are associated with the response of these patients to immunotherapy—mainly PD-1 targeted drugs such as nivolumab (trade name Opdivo) and pembrolizumab (trade name Keytruda). ...
The research summarized in this whitepaper provides a number of examples of how ALZET® pumps offer a superior pre-clinical drug dosing option for the delivery of a wide array of anti-cancer agents, including small molecules, immunotherapies, radiotherapies, combination treatments, and novel drug entities. ...
The reason value-based agreements have created buzz is because gene, cellular and immunotherapies are risky endeavors for drug developers. To enable research, development and access to these high-priced drug therapies, biopharmaceutical companies understand that the way they do reimbursements must change. ...